Alzheimer’s disease, a progressive brain disorder that gradually degrades a person’s cognitive and memory functions, is the No. 1 cause of dementia. There’s currently no cure, but according to a study published in the journal ACS Chemical Neuroscience, a new copper-based treatment may be on the horizon.
Clearing out
Alzheimer’s is “driven by the buildup of toxic proteins called amyloid beta,” said a release about the study. These proteins are usually flushed into the bloodstream through the blood-brain barrier. However, in those with Alzheimer’s disease, the “pumps doing the heavy lifting, called P-glycoprotein (P-gp), weaken significantly, clogging the drain and trapping the toxic proteins in the brain.”
A buildup of these proteins in the brain leads to memory loss and cognitive decline. But the copper-based compound Cu(ATSM), which has “anti-inflammatory and neuroprotective properties,” can clear them from the brain, said senior study author Joseph Nicolazzo in the release. It does so by “increasing the number and activity” of the P-gp pumps, said Newsweek.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
SUBSCRIBE & SAVE
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Latest Videos FromThe Week
The study is the first to show that Cu(ATSM) can boost the amount of P-gp pumps “by 24.1%, effectively linking the repair of the blood-brain barrier to a reduction in toxic proteins and improved cognitive function,” said lead study author Jae Pyun in the release. “Over 56 days, the treatment reduced toxic amyloid-beta by 42% and improved spatial learning by nearly 44%.”
Not just yet
Alzheimer’s disease is the No. 1 cause of dementia, accounting for about 60% to 80% of cases, according to the Alzheimer’s Association. The condition also worsens over time. In its early stages, “memory loss is mild, but with late-stage Alzheimer’s, individuals lose the ability to carry on a conversation and respond to their environment,” said the association. “On average, a person with Alzheimer’s lives four to eight years after diagnosis but can live as long as 20 years, depending on other factors.”
Cu(ATSM) improved the long-term spatial memory of mice, showing promise for future human clinical trials. The compound has also “already progressed to clinical testing for conditions like Parkinson’s and ALS,” said Nicolazzo in the release. However, “despite its promising results in animals, a pilot comparative analysis found that Cu(ATSM) provided no significant benefit to humans with ALS,” said Science Alert.
More than 7 million Americans 65 and older are estimated to be living with Alzheimer’s. By 2050, that number is projected to rise to close to 13 million, according to the Alzheimer’s Association. A drug that could prolong cognition and lifespan would be a game changer for patients and their families.
The disease itself is still full of unknowns. Alzheimer’s “involves the biological environment of the aging brain, including membrane biology, inflammation, vascular function, lipid metabolism and cellular resilience,” said neuroscientist Dayan Goodenowe to Newsweek. “So any single mechanism still has to be validated before we know whether it produces meaningful clinical benefit.”
